Arch Therapeutics (ARTH) announced positive results from a first-in-human study of its AC5 Topical Hemostatic Device in skin lesion patients with bleeding wounds. Results showed a median time to hemostasis (bleeding has stopped) was 41% faster in the AC5 cohort compared to control. All wounds healed satisfactorily with no serious adverse events reported, including patients on antiplatelet therapy (blood thinners). The company plans to included the data in its CE Mark application in Europe.